Toremifene is a selective estrogen receptor modulator (SERM) that also moderates androgen receptor activity as well. Toremifene displays anticancer chemotherapeutic and anti-angiogenic activities. Clinically, this compound is used to treat breast cancer and prostate cancer. Toremifene decreases microvessel density and induces remission of benign fibrous lesions in clinical settings with subjects experiencing desmoid tumors. Additionally, toremifene increases latency to tumor formation, decreases tumor number, and increases survival in animal models of prostate cancer.